Oncology
Treatment of Advanced Lymphomas with Bleomycin (NSC-125066)Supported in part by Public Health Service Grant CA-05186 from the National Cancer Institute, National Institutes of Health, Department of Health, Education, and Welfare Oncology Service, School of Medicine, and Medical Center, University of Southern California, Los Angeles, California City of Hope Medical Center, Duarte, California Ellis Fischel State Cancer Hospital, Columbia, Mississippi
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: June 09, 2009
Issue release date: 1976
Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0
ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)
For additional information: https://www.karger.com/OCL
Abstract
88 patients with far-advanced lymphomatous malignancy were treated with Bleomycin given by either intramuscular (i. m.) or intravenous (i. v.) injection according to a randomized treatment assignment. Response occurred most frequently in Hodgkin’s disease (i. m. 7/24; i. v. 4/18), least often in histiocytic lymphomas (i. m. 0/8; i. v. 1/8), and with intermediate frequency in lymphocytic lymphomas (i. m. 3/16; i. v. 0/14). While toxicity was common (70%), severe toxicity was unusual (8%) with severe pulmonary toxicity occurring in four patients (three i. m.; one i.v.). All three drug associated deaths occurred in i. m. patients. Unexpected life-threatening pericarditis occurred in two i. m. treated patients. Although response and drug related deaths occureed more often in the i. m. patients, the comparison with i. v. patients was not statistically different.
© 1976 S. Karger AG, Basel
Related Articles:
Article / Publication Details
Published online: June 09, 2009
Issue release date: 1976
Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 0
ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)
For additional information: https://www.karger.com/OCL
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Get Permission